{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T15:00:28Z","timestamp":1788102028074,"version":"build-2803163510"},"reference-count":14,"publisher":"SAGE Publications","issue":"6","license":[{"start":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T00:00:00Z","timestamp":1500508800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T00:00:00Z","timestamp":1500508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Microbial Drug Resistance"],"published-print":{"date-parts":[[2017,9,1]]},"abstract":"<jats:p>\n                    A total of 8,072 gram-positive isolates collected from 69 medical centers among all 9 U.S. Census Divisions during the 2015 SENTRY Antimicrobial Surveillance Program were included. Telavancin had minimal inhibitory concentration (MIC)\n                    <jats:sub>50<\/jats:sub>\n                    and MIC\n                    <jats:sub>90<\/jats:sub>\n                    values of 0.03\/0.06 \u03bcg\/mL, respectively, against methicillin-susceptible (MSSA) and methicillin-resistant\n                    <jats:italic toggle=\"yes\">Staphylococcus aureus<\/jats:italic>\n                    (MRSA). Similar activity was also observed among coagulase-negative staphylococci (MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    , 0.03\/0.06\u2009\u03bcg\/ml; 100.0% inhibited by \u22640.12\u2009\u03bcg\/ml). Telavancin was active against vancomycin-susceptible\n                    <jats:italic toggle=\"yes\">Enterococcus faecalis<\/jats:italic>\n                    (MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    , 0.12\/0.12\u2009\u03bcg\/ml) and\n                    <jats:italic toggle=\"yes\">Enterococcus faecium<\/jats:italic>\n                    (MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    , 0.03\/0.06\u2009\u03bcg\/ml), but was less active against vancomycin-resistant\n                    <jats:italic toggle=\"yes\">E. faecium<\/jats:italic>\n                    (MIC\n                    <jats:sub>90<\/jats:sub>\n                    , &gt;2\u2009\u03bcg\/ml) and\n                    <jats:italic toggle=\"yes\">E. faecalis<\/jats:italic>\n                    (MIC\n                    <jats:sub>90<\/jats:sub>\n                    , &gt;2\u2009\u03bcg\/ml). Streptococci showed modal MIC results of 0.008\u2009\u03bcg\/ml (\n                    <jats:italic toggle=\"yes\">Streptococcus pneumoniae<\/jats:italic>\n                    ) to 0.015\u2009\u03bcg\/ml (\u03b2-hemolytic streptococci and viridans group streptococci). Potency variations for telavancin within Census Divisions were not observed. Telavancin remains potent\n                    <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                    against indicated pathogens recovered from U.S. medical centers (2015).\n                  <\/jats:p>","DOI":"10.1089\/mdr.2017.0022","type":"journal-article","created":{"date-parts":[[2017,7,20]],"date-time":"2017-07-20T17:23:49Z","timestamp":1500571429000},"page":"718-726","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":10,"title":["<i>In Vitro<\/i>\n                    Activity of Telavancin Against Clinically Important Gram-Positive Pathogens from 69 U.S. Medical Centers (2015): Potency Analysis by U.S. Census Divisions"],"prefix":"10.1177","volume":"23","author":[{"given":"Michael A.","family":"Pfaller","sequence":"first","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer I.","family":"Smart","sequence":"additional","affiliation":[{"name":"Theravance Biopharma US, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2017,7,20]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq031"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S25930"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/587896"},{"key":"e_1_3_3_5_2","unstructured":"VIBATIV Package Insert. 2016. Available at http:\/\/www.vibativ.com. Theravance Biopharma US Inc (accessed 25August2016)."},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01641-07"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04052-14"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.3.1127-1134.2005"},{"key":"e_1_3_3_9_2","unstructured":"CLSI. 2016. M100-S26. Performance Standards for Antimicrobial Susceptibility Testing: 26th Informational Supplement. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03172-14"},{"key":"e_1_3_3_11_2","unstructured":"CLSI. 2015. M07-A10. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard\u2014Tenth Edition. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_3_12_2","unstructured":"EUCAST. 2016. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0. Available at www.eucast.org\/clinical_breakpoints\/ (accessed 5January2016)."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02803-15"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2012.02.001"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2012.03.038"}],"container-title":["Microbial Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/mdr.2017.0022","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2017.0022","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/mdr.2017.0022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T20:31:35Z","timestamp":1777667495000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/mdr.2017.0022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,20]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,9,1]]}},"alternative-id":["10.1089\/mdr.2017.0022"],"URL":"https:\/\/doi.org\/10.1089\/mdr.2017.0022","relation":{},"ISSN":["1076-6294","1931-8448"],"issn-type":[{"value":"1076-6294","type":"print"},{"value":"1931-8448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,20]]}}}